New frontiers in translational research in neuro-oncology and the blood-brain barrier: Report of the Tenth Annual Blood-brain Barrier Disruption Consortium Meeting

Clinical Cancer Research

Volumn 11, Issue 2 I, 2005, Pages 421-428

  Doolittle, Nancy D ^a   Abrey, Lauren E ^b   Bleyer, W Archie ^c   Brem, Steven ^d   Davis, Thomas P ^e   Dore Duffy, Paula ^f   Drewes, Lester R ^g   Hall, Walter A ^h   Hoffman, John M ⁱ   Korfel, Agnieszka ^j   Martuza, Robert ^k   Muldoon, Leslie L ^a   Peereboom, David ^l   Peterson, Darryl R ^m   Rabkin, Samuel D ⁿ   Smith, Quentin ^o   Stevens, Glen H J ^l   Neuwelt, Edward A ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^f WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^h UNIVERSITY OF MINNESOTA   (United States)

ⁱ NATIONAL CANCER INSTITUTE   (United States)

^j CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^k MASSACHUSETTS GENERAL HOSPITAL   (United States)

^l LERNER RESEARCH INSTITUTE   (United States)

^m The Chicago Medical College   (United States)

ⁿ HARVARD MEDICAL SCHOOL   (United States)

^o TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 CHLOROETHYL) 3 (2,6 DIOXO 3 PIPERIDYL) 1 NITROSOUREA; ACETYLCYSTEINE; ANGIOGENESIS INHIBITOR; ANTIOXIDANT; CADHERIN; CANCER VACCINE; CARBOPLATIN; ERLOTINIB; ETOPOSIDE; EXHERIN; GADOLINIUM; GLUTATHIONE; METHIONINE; METHOTREXATE; NAVELBINE; SODIUM THIOSULFATE; TEMOZOLOMIDE; THALIDOMIDE; THIOL DERIVATIVE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG;

ANGIOGENESIS; BLOOD BRAIN BARRIER; BRAIN LYMPHOMA; BRAIN METASTASIS; BRAIN TUMOR; CELL TRANSPORT; CENTRAL NERVOUS SYSTEM DISEASE; CONFERENCE PAPER; CYTOLOGY; DIAGNOSTIC IMAGING; ENDOTHELIUM CELL; GENE THERAPY; GLIA; GLIOMA; HUMAN; HUMAN CELL; IMMUNOTHERAPY; MEDICAL RESEARCH; NERVE CELL; ONCOLOGICAL PARAMETERS; ORGANIZATION; PERICYTE; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DRUG DELIVERY SYSTEMS; DRUG IMPLANTS; HUMANS; MAGNETIC RESONANCE IMAGING; MEDICAL ONCOLOGY; NEUROLOGY;

EID: 19944426039     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (50)

1. Huber JD, Egleton RD, Davis TP. Molecular physiology and pathophysiology of tight junctions in the blood-brain barrier. Trends Neurosci 2001;24:719-25.
2. Neuwelt EA. Mechanisms of disease: the blood-brain barrier. Neurosurgery 2004;54:131-42.
3. Taylor EM. The impact of efflux transporters in the brain on the development of drugs for CNS disorders. Clin Pharmacokinet 2002;41:81-92.
4. Shusta EV, Boado RJ, Mathem GW, Pardridge WM. Vascular genomics of the human brain. J Cereb Blood Flow Metab 2002;22:245-52.
5. Witt KA, Mark KS, Hom S, Davis TP. Effects of hypoxia-reoxygenation on rat blood-brain barrier permeability and tight junctional protein expression. Am J Physiol Heart Circ Physiol 2003;285:H2820-31.
6. Marchi N, Cavaglia M, Fazio V, Bhudia S, Hallene K, Janigro D. Peripheral markers of blood-brain barrier damage. Clin Chim Acta 2004;342:1-12.
7. Lee HJ, Pardridge WM. Monoclonal antibody radiopharmaceuticals: cationization, pegylation, radiometal chelation, pharmacokinetics, and tumor imaging. Bioconjug Chem 2003;14:546-53.
8. Ningaraj NS, Rao MK, Black KL. Adenosine 5′-triphosphate-sensitive potassium channel-mediated blood-brain barrier permeability increase in a rat brain tumor model. Cancer Res 2003;63:8899-911.
9. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM. P-glycoprotein: from genomics to mechanism. Oncogene 2003;22:7468-85.
10. Fellner S, Bauer B, Miller DS, et al. Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J Clin Invest 2002;110:1309-18.
11. Kemper EM, van Zandbergen AE, Cleypool C, et al. Increased penetration of paclitaxel into the brain by inhibition of P-glycoprotein. Clin Cancer Res 2003;9:2849-55.
12. Robert J, Jarry C. Multidrug resistance reversal agents. J Med Chem 2003;46:4805-17.
13. 14C-sucrose in RG-2 rat gliomas after intravenous and convection-enhanced delivery. Neuro-oncol 2004;6:104-12 [serial on the Internet]. 2004 [cited 2004 Mar 3]; Available from: http://neuro-oncology.mc. duke.edu. [posted to Neuro-Oncol Doc. 03-044].
14. Dickey DT, Muldoon LL, Kraemer DF, Neuwelt EA. Protection against cisplatin-induced ototoxicity and nephrotoxicity by N-acetylcysteine in a rat model. Hearing Res 2004;193:25-30.
15. Neuwelt EA, Pagel MA, Kraemer DF, Peterson DR, Muldoon LL. Bone marrow chemoprotection without compromise of chemotherapy efficacy in a rat brain tumor model. J Pharmacol Exp Ther 2004;309:594-9.
16. Doolittle ND, Muldoon LL, Brummett RE, et al. Delayed sodium thiosulfate as an otoprotectant against carboplatin-induced hearing loss in patients with malignant brain tumors. Clin Cancer Res 2001;7:493-500.
17. Neuwelt EA, Pagel MA, Hasler BP, Deloughery TG, Muldoon LL. Therapeutic efficacy of aortic administration of N-acetylcysteine as a chemoprotectant against bone marrow toxicity after intracarotid administration of alkylators, with or without glutathione depletion in a rat model. Cancer Res 2001;61:7868-74.
18. Alberts DS, Bleyer WA. Future development of amifostine in cancer treatment. Semin Oncol 1996;23:90-9.
19. Bello L, Giussani C, Carrabba G, Pluderi M, Costa F, Bikfavi A. Angiogenesis and invasion in gliomas. Cancer Treat Res 2004;117:263-84.
20. Brem S. Angiogenesis and brain tumors. In: Winn HR, editor. Youmans neurological surgery, Vol. 1. 5th ed. Philadelphia (PA): Elsevier Inc; 2004. p. 771-89. Chap. 38.
21. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/ leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21:60-5.
22. Balabanov R, Dore-Duffy P. Role of the CNS microvascular pericyte in the blood-brain barrier. J Neurosci Res 1998;53:637-44.
23. Ferrari N, Glod J, Lee J, Kobiler D, Fine HA. Bone marrow-derived, endothelial progenitor-like cells as angiogenesis-selective gene-targeting vectors. Gene Ther 2003;10:647-56.
24. Nourhaghighi N, Teichert-Kuliszewska K, Davis J, Stewart DJ, Nag S. Altered expression of angiopoietins during blood-brain barrier breakdown and angiogenesis. Lab Invest 2003;83:1211-22.
25. Sun J, Blaskovich MA, Jain RK, et al. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor. Cancer Res 2004;64:3586-92.
26. Abdollahi A, Lipson EE, Sckell A, et al. Combined therapy with direct and indirect angiogenesis inhibition results in enhanced anti-angiogenic and antitumor effects. Cancer Res 2003;63:8890-8.
27. Justman QA, Clinton GM. Herstatin, an autoinhibitor of the human epidermal growth factor receptor 2 tyrosine kinase, modulates epidermal growth factor signaling pathways resulting in growth arrest. J Biol Chem 2002;277:20618-24.
28. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998;90:1473-9.
29. Hall WA. Extending survival in gliomas: surgical resection or immunotherapy? Surg Neurol 2004;61:145-8.
30. Jensen MC, Clarke P, Tan G, et al. Human T lymphocyte genetic modification with naked DNA. Mol Ther 2000;1:49-55.
31. Kim D, Martuza RL, Zwiebel J. Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nat Med 2001;7:781-7.
32. Muldoon LL, Nilaver G, Kroll RA, et al. Comparison of intracerebral inoculation and osmotic blood-brain barrier disruption for delivery of adenovirus, herpesvirus and iron oxide particles to normal rat brain. Am J Pathol 1995;147:1840-3.
33. Mojsilovic-Petrovic J, Nesic M, Pen A, Stanimirovic D, Zhang W. Development of rapid staining protocols for laser-capture microdissection of brain vessels from human and rat coupled to gene expression analyses. J Neurosci Methods 2004;133:39-48.
34. Braaten KM, Betensky RA, de Leval L, et al. BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma. Clin Cancer Res 2003;9:1063-9.
35. Korfel A, Thiel E. Chemotherapy for primary CNS lymphoma (PCNSL) [abstract]. J Cancer Res Clin Oncol 2004; Suppl 130:ISO96.
36. Soussain C, Suzan F, Hoang-Xuan K, et al. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol 2001;19:742-9.
37. Abrey LE, Moskowitz CH, Mason WP, et al. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol 2003;21:4151-6.
38. Batchelor T, Carson K, O'Neill A, et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol 2003;21:1044-9.
39. McAllister LD, Doolittle ND, Guastadisegni PE, et al. Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery 2000;46:51-60; discussion 60-1.
40. Kraemer DF, Fortin D, Doolittle ND, Neuwelt EA. Association of total dose intensity of chemotherapy in primary central nervous system lymphoma (human non-acquired immunodeficiency syndrome) and survival. Neurosurgery 2001;48:1033-41.
41. Smith JR, Rosenbaum JT, Wilson DJ, et al. Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement. Ophthalmology 2002;109:1709-16.
42. Rubenstein JL, Shen A, Abrey L, et al. Results from a phase I study of intraventricular administration of rituximab in patients with recurrent lymphomatous meningitis. Proc Am Soc Clin Oncol 2004;23:578; abstract 6593.
43. Ferreri AJ, Batchelor T, Zucca E, Cavalli F, Armitage J. International collaborative group against primary CNS lymphomas. J Clin Oncol 2003;21:1649-50.
44. Suh JH, Stea BD, Kresl JJ, et al. A phase 3, randomized, open-label, comparative study of standard whole brain radiation therapy (WBRT) with supplemental oxygen (02), with or without RSR13, in patients with brain metastases. Neuro-oncol 2003;5:345. Abstract RT-13.
45. Newton HB, Slivka MA, Volpi C, et al. Intra-arterial carboplatin and intravenous etoposide for the treatment of metastatic brain tumors. J Neurooncol 2003;61:35-44.
46. 11C]methionine. Eur J Nucl Med Mol Imaging 2003;30:1561-7.
47. Knopp MV, Runge VM, Essig M, et al. Primary and secondary brain tumors at MR imaging: bicentric intraindividual crossover comparison of gadobentate dimeglumine and gadopentetate dimeglumine. Radiology 2004;230:55-64.
48. Kircher MF, Mahmood U, King RS, Weissleder R, Josephson L. A multimodal nanoparticle for preoperative magnetic resonance imaging and intraoperative optical brain tumor delineation. Cancer Res 2003;63:8122-5.
49. Varallyay P, Nesbit G, Muldoon LL, et al. Comparison of two superparamagnetic viral-sized iron oxide particles ferumoxides and ferumoxtran-10 with a gadolinium chelate in imaging intracranial tumors. AJNR Am J Neuroradiol 2002;23:510-9.
50. Neuwelt EA, Varallyay P, Bago A, Muldoon LL, Nesbit G, Nixon R. Imaging of iron oxide nanoparticles by MR and light microscopy inpatients with malignant brain tumors. Neuropathol Appl Neurobiol 2004;30:70.